Importantly, the mechanisms of EGFR TKI resistance elucidated to date can encompass multiple mechanisms simultaneously in one patient or even tumour, creating significant obstacles for designing better treatment strategies for patients (Pao and Chmielecki, 2010; Chong and Jänne, 2013). Here, EGFR is linked to neoplasm.